CN112969696B - 乙酰化书写器抑制剂的开发及其用途 - Google Patents
乙酰化书写器抑制剂的开发及其用途 Download PDFInfo
- Publication number
- CN112969696B CN112969696B CN201980072584.4A CN201980072584A CN112969696B CN 112969696 B CN112969696 B CN 112969696B CN 201980072584 A CN201980072584 A CN 201980072584A CN 112969696 B CN112969696 B CN 112969696B
- Authority
- CN
- China
- Prior art keywords
- cpd
- cancer
- represented
- bifunctional compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754934P | 2018-11-02 | 2018-11-02 | |
| US62/754,934 | 2018-11-02 | ||
| PCT/US2019/059401 WO2020092907A1 (en) | 2018-11-02 | 2019-11-01 | Acetylation writer inhibitor development and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112969696A CN112969696A (zh) | 2021-06-15 |
| CN112969696B true CN112969696B (zh) | 2024-06-11 |
Family
ID=70463920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980072584.4A Active CN112969696B (zh) | 2018-11-02 | 2019-11-01 | 乙酰化书写器抑制剂的开发及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12428412B2 (enExample) |
| EP (1) | EP3873898B1 (enExample) |
| JP (1) | JP7712867B2 (enExample) |
| CN (1) | CN112969696B (enExample) |
| AU (1) | AU2019371400B2 (enExample) |
| CA (1) | CA3118597A1 (enExample) |
| ES (1) | ES3038078T3 (enExample) |
| WO (1) | WO2020092907A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN111217802B (zh) * | 2018-11-27 | 2021-10-08 | 海创药业股份有限公司 | 一类组蛋白乙酰化酶p300抑制剂及其用途 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| WO2020257278A2 (en) * | 2019-06-18 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116133692A (zh) | 2020-07-30 | 2023-05-16 | 凯麦拉医疗公司 | 治疗突变淋巴瘤的方法 |
| WO2022042707A1 (en) * | 2020-08-27 | 2022-03-03 | Cullgen (Shanghai) , Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022233431B2 (en) * | 2021-03-09 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Ep300 degrader and uses thereof in neuroblastoma |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CN116375717B (zh) * | 2021-12-30 | 2025-10-28 | 成都先导药物开发股份有限公司 | 螺环化合物及其双功能化合物和用途 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| GB202209404D0 (en) * | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| JP2025137900A (ja) * | 2022-08-10 | 2025-09-25 | 住友ファーマ株式会社 | 第４級炭素で置換された３級アミド誘導体 |
| JP2025524008A (ja) * | 2022-09-07 | 2025-07-25 | 成都先導薬物開発股▲フン▼有限公司 | スピロ化合物及びその用途 |
| CN119255996B (zh) * | 2022-09-08 | 2026-04-24 | 成都先导药物开发股份有限公司 | 螺环化合物及其用途 |
| WO2024064358A1 (en) * | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR20250075705A (ko) | 2022-10-07 | 2025-05-28 | 화이자 인코포레이티드 | Hsd17b13 억제제 및/또는 분해제 |
| EP4634169A1 (en) | 2022-12-16 | 2025-10-22 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| CN116178339B (zh) * | 2023-02-20 | 2024-08-06 | 杭州医学院 | 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用 |
| GB202302941D0 (en) | 2023-02-28 | 2023-04-12 | Tocris Cookson Ltd | Proteolysis-targeting chimeras |
| WO2025120592A1 (en) | 2023-12-07 | 2025-06-12 | Pfizer Inc. | Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044770A1 (en) * | 2014-09-18 | 2016-03-24 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197036A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| KR20190084063A (ko) * | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020257278A2 (en) * | 2019-06-18 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
-
2019
- 2019-11-01 CN CN201980072584.4A patent/CN112969696B/zh active Active
- 2019-11-01 AU AU2019371400A patent/AU2019371400B2/en active Active
- 2019-11-01 EP EP19878099.1A patent/EP3873898B1/en active Active
- 2019-11-01 WO PCT/US2019/059401 patent/WO2020092907A1/en not_active Ceased
- 2019-11-01 CA CA3118597A patent/CA3118597A1/en active Pending
- 2019-11-01 ES ES19878099T patent/ES3038078T3/es active Active
- 2019-11-01 JP JP2021523897A patent/JP7712867B2/ja active Active
- 2019-11-01 US US17/289,662 patent/US12428412B2/en active Active
-
2025
- 2025-07-08 US US19/262,282 patent/US20250333402A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044770A1 (en) * | 2014-09-18 | 2016-03-24 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197036A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
Also Published As
| Publication number | Publication date |
|---|---|
| US12428412B2 (en) | 2025-09-30 |
| WO2020092907A1 (en) | 2020-05-07 |
| US20220009916A1 (en) | 2022-01-13 |
| EP3873898A4 (en) | 2022-11-30 |
| EP3873898A1 (en) | 2021-09-08 |
| EP3873898B1 (en) | 2025-05-28 |
| US20250333402A1 (en) | 2025-10-30 |
| CN112969696A (zh) | 2021-06-15 |
| ES3038078T3 (en) | 2025-10-09 |
| AU2019371400A1 (en) | 2021-04-08 |
| AU2019371400B2 (en) | 2024-10-17 |
| JP2022512900A (ja) | 2022-02-07 |
| CA3118597A1 (en) | 2020-05-07 |
| JP7712867B2 (ja) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112969696B (zh) | 乙酰化书写器抑制剂的开发及其用途 | |
| US20250388562A1 (en) | Small molecule degraders of helios and methods of use | |
| JP7631434B2 (ja) | セレブロン（ｃｒｂｎ）に対するリガンド | |
| US20230002397A1 (en) | Small molecule degraders of helios and metods of use | |
| US12234220B2 (en) | Immunomodulatory compounds | |
| US20210277018A1 (en) | New crbn modulators | |
| JP7626721B2 (ja) | 小分子標的ブロモ／アセチルタンパク質およびその使用 | |
| US20240409528A1 (en) | Binders of cereblon and methods of use thereof | |
| US20230192644A1 (en) | Piperidine-2,6-diones as small molecule degraders of helios and methods of use | |
| EP4460306A2 (en) | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) | |
| HK40055968B (en) | Histone acetylation writer inhibitor development and uses thereof | |
| HK40055968A (en) | Histone acetylation writer inhibitor development and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |